anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Tenofovir
Trial phase: Not Applicable
SMILES: C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 229
Group description: Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.

Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Eligibility criteria:
Inclusion Criteria:

Former TDF 2 participants
Willing and able to provide informed written consent for participation
If female, willing to use effective contraception during the trial (oral or injectable hormonal contraception, an intrauterine device [IUD], or who have had surgical interventions such as bilateral tubal ligation or hysterectomy)
Laboratory values as follows within 30 days prior to enrollment:
HIV uninfected by dual, parallel, rapid whole blood testing and HIV EIA
Serum phosphorus ≥ 2.2 mg/dL
Calculated creatinine clearance ≥ 60 mL/min

Exclusion Criteria:

Positive urine pregnancy test (females)
Breastfeeding (females)
History of significant renal or bone disease
Any other clinical condition or prior therapy that, in the opinion of the physician would make the subject unsuitable for the OLE or unable to comply with the dosing requirements
Intervention: Phenobarbital
Trial phase: Phase 3
ATC code: N03AA02 | N05CB01
SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 3
Group description: Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).

Phenobarbital Sodium Injection: The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
Eligibility criteria:
Inclusion Criteria:

Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral hemorrhage, central nervous system infection)
Parental informed consent (in-person or remote consent)
Undergoing continuous video electroencephalogram (cvEEG) monitoring
Has evidence of electrographic seizure burden of at least 30 seconds/h

Exclusion Criteria:

Received anticonvulsant treatment, including phenobarbital, prior to randomization (with exception of lorazepam administered for sedation > 24 hours before enrollment)
Strong suspicion or confirmed diagnosis of brain malformation, inborn error of metabolism genetic syndrome, or major congenial malformation prior to randomization
Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic disorder
Death appears to be imminent as assessed by the NICU attending physician
Is currently enrolled in another study assessing the same and/or similar primary/secondary endpoints with/without drug treatment.
Intervention: Phenobarbital
Trial phase: Phase 3
ATC code: N03AA02 | N05CB01
SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 1
Group description: Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).

Phenobarbital Sodium Injection: The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
Eligibility criteria:
Inclusion Criteria:

Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral hemorrhage, central nervous system infection)
Parental informed consent (in-person or remote consent)
Undergoing continuous video electroencephalogram (cvEEG) monitoring
Has evidence of electrographic seizure burden of at least 30 seconds/h

Exclusion Criteria:

Received anticonvulsant treatment, including phenobarbital, prior to randomization (with exception of lorazepam administered for sedation > 24 hours before enrollment)
Strong suspicion or confirmed diagnosis of brain malformation, inborn error of metabolism genetic syndrome, or major congenial malformation prior to randomization
Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic disorder
Death appears to be imminent as assessed by the NICU attending physician
Is currently enrolled in another study assessing the same and/or similar primary/secondary endpoints with/without drug treatment.
Intervention: Colchicine
Trial phase: Phase 3
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2195
Group description: Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Eligibility criteria:
Inclusion Criteria:

Males and females, at least 40 years of age, capable and willing to provide informed consent;
Patient must have received a diagnosis of COVID-19 infection within the last 24 hours;
Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization);
Patient must possess at least one of the following high-risk criteria: 70 years or more of age, obesity (BMI ≥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, fever of ≥38.4°C within the last 48 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia, or the combination of high neutrophil count and low lymphocyte count;
Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after study completion;
Patient must be able and willing to comply with the requirements of this study protocol.

Exclusion Criteria:

Patient currently hospitalized or under immediate consideration for hospitalization;
Patient currently in shock or with hemodynamic instability;
Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption;
Patient with pre-existent progressive neuromuscular disease;
Estimated Glomerular filtration rate (eGFR), using the MDRD equation for all subjects being considered for enrollment, with a cut-off of < 30 mL/m in/1.73m2;
Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease;
Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication;
Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout);
Patient with a history of an allergic reaction or significant sensitivity to colchicine;
Patient undergoing chemotherapy for cancer;
Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Intervention: Calcitriol
Trial phase: Phase 4
ATC code: A11CC04 | D05AX03
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: 35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units

Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
Eligibility criteria:
Inclusion Criteria:

Candidate for first-time elective CABG surgery for coronary artery disease (CAD)
Coronary artery surgery only (i.e. no valvular surgery)
Cardiopulmonary pump used during surgery
Vitamin D level below 30 ng/ml

Exclusion Criteria:

Renal failure or creatinine level >1.5 mg/dl
Previous use of vitamin D supplement
Intervention: Azithromycin
Trial phase: Phase 2
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: Azithromycin: Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
Eligibility criteria:
Inclusion Criteria:

Adult (age ≥ 18 years)

Confirmed OR suspected COVID-19,

Confirmed: Positive assay for COVID-19 within the last 10 days
Suspected: Pending assay for COVID-19 WITH high clinical suspicion
Scheduled for admission or already admitted to an inpatient bed

Exclusion Criteria:

Allergy to hydroxychloroquine or azithromycin
History of bone marrow transplant
Known G6PD deficiency
Chronic hemodialysis or Glomerular Filtration Rate < 20ml/min
Psoriasis
Porphyria
Concomitant use of digitalis, flecainide, amiodarone, procainamide, propafenone, cimetidine, dofetilide, phenobarbital, phenytoin, or sotalol
Known history of long QT syndrome
Current known QTc>500 msec
Pregnant or nursing
Prisoner
Weight < 35kg
Seizure disorder
Severe liver disease
Outpatient use of hydroxychloroquine for treatment of a disease other than COVID-19 OR has received more than 2 days of hydroxychloroquine or azithromycin for suspected or confirmed COVID-19
Patient has recovered from COVID-19 and/or is being discharged from the hospital on day of enrollment.
Treating physician refuses to allow patient participation in the study
Unable to obtain informed consent
Prior enrollment in this study
Intervention: Kenalog
Trial phase: Phase 2
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1
Group description: The experimental group will receive a single 32 mg Zilretta injection approximately 8 weeks after meniscus surgery.

Zilretta: ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
Eligibility criteria:
Inclusion Criteria:

Written consent to participate in the study
Male or female greater than or equal to 18 years of age and less than 40 years of age
Has been consented to undergo arthroscopic ACL reconstruction with partial meniscectomy or meniscal repair
Ambulatory and in good general health
Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.
Willing to abstain from use of protocol-restricted medications during the study
Females and males who have reproductive potential: Must use highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation (10 weeks; 4 to 14 weeks after surgery)
Demonstrate persistent inflammation defined as synovial fluid IL-1a concentration greater than or equal to 5 pg/mL at the time of surgery

Exclusion Criteria:

Known allergic reactions to components of the extended-release triamcinolone acetonide (Zilretta®)
Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
History of infection in either knee joint
Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening
Other surgery or arthroscopy of either knee within 6 months of Screening
Intraarticular treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation or any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).
Intraarticular treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
Females who are pregnant or nursing or plan to become pregnant during the study; men whose female partner plans to conceive during the study
Radiographic osteoarthritic changes defined as Kellgren-Lawrence grade 2 or greater (as determined by PI from patient's preoperative X-rays)
Inability to read and understand English
Intervention: Azithromycin
Trial phase: Phase 3
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 145
Group description: 1.2g of oral azithromycin

Azithromycin: Participants will be shipped a single 1.2 g dose of oral azithromycin
Eligibility criteria:
Inclusion Criteria:

Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days
Not currently hospitalized
Willing and able to receive study drug by mail
Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone
No known allergy or other contraindication to macrolides
Age 18 years or older at the time of enrollment
No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)
No recent use of hydroxychloroquine within the past 7 days for participants >55 years of age
Not currently taking nelfinavir or warfarin (Coumadin)
Provision of informed consent
Not currently pregnant
Intervention: Roxithromycin
Trial phase: Phase 3
ATC code: J01FA06
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=NOCOCCOC)C(C)C(O)C1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1722
Group description: Education and surveillance plus M-M-R II ®

MR or M-M-R II ® vaccine: Education and surveillance plus MR or M-M-R II ® vaccine
Eligibility criteria:
Inclusion criteria

Volunteers without clinical evidence of COVID-19 infection aged 18 years and older.
Healthcare workers based in a primary, secondary or tertiary healthcare setting with a high risk of developing COVID-19 due to their potential exposure to patients with SARS-CoV-2 infection.
Must have a mobile phone and access to the Internet for data collection purposes.
Participants who are willing and able to provide informed consent via an electronic consent process.

Exclusion criteria

Prior enrollment into other COVID-19 interventional prevention or treatment trials (observational trials not excluded).
Self-reported or diagnosed current infection with SARS-CoV-2 or previous COVID-19 diagnosis.
Self-reported current acute respiratory infection.
Concurrent and/or recent involvement in other research or use of the investigational product, a product considered to be equivalent to the investigational product, or any other product that is likely to interfere with the investigational products in this trial used within three months of study enrolment.
Self-reported known allergies to any of the IMPs and excipients of the IMPs and placebo.
Self-reported presence or history of the conditions listed in the appendices.
Self-reported current use of medication known to interact with any of the medications listed in the appendices.
Inability or unwillingness to be followed up for the trial period.

For M-M-R II

Pregnant women.
Individuals receiving high dose corticosteroids, other immuno-suppressive drugs, alkylating agents or anti-metabolites.
Individuals undergoing radiotherapy.
Any malignant disease either untreated or currently undergoing therapy.
History of administration of gammaglobulin or blood transfusions within the previous 3 months.
Participants with an allergy to the MR (MMR) vaccine or its components, including neomycin.
Idiopathic thrombocytopenic purpura (ITP)
Untreated tuberculosis
Prior receipt of any vaccines (licensed or investigational) ≤30 days before enrollment
Planned receipt of any vaccine other than the study intervention within 30 days before and after the study vaccination (not including the flu vaccination via injection)
Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines).
Any confirmed or suspected immunosuppressive or immunodeficient state, including untreated HIV infection with a CD4T count <200 /mL
Asplenia
Intervention: Ataluren
Trial phase: Phase 2
ATC code: M09AX03
SMILES: O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Sex: Male
Age groups: Child
Healthy volunteers: No
Participants at risk: 6
Group description: Participants received ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for up to 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Body weight ≥7.5 kilograms (kg)
Diagnosis of duchenne muscular dystrophy (DMD) based on an elevated serum creatine kinase and genotypic evidence of dystrophinopathy.
Documentation of the presence of a nonsense mutation of the dystrophin gene as determined by gene sequencing prior to enrollment.

Exclusion Criteria:

Participation in any drug or device investigation or whose sibling is currently participating in a blinded portion of another ataluren study or received an investigational drug within three months prior to the Screening Visit or who anticipate participating in any other drug or device clinical investigation or receiving any other investigational drug within the duration of this study.
Expectation of a major surgical procedure during the study period.
Known hypersensitivity to any of the ingredients or excipients of the study drug (polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium stearate).

Ongoing use of the following drugs:

Systemic aminoglycoside therapy and/or intravenous (IV) vancomycin.
Coumarin-based anticoagulants (for example, warfarin), phenytoin, tolbutamide, or paclitaxel.
Inducers of UGT1A9 (for example, rifampicin), or substrates of OAT1 or OAT3 (for example, ciprofloxacin, adefovir, oseltamivir, aciclovir, captopril, furosemide, bumetanide, valsartan, pravastatin, rosuvastatin, atorvastatin, pitavastatin).
Intervention: Morphine
Trial phase: Phase 4
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: People with low back pain who were given and oral dose of 30 mg morphine.

Morphine: 30 mg oral tablet
Eligibility criteria:
Inclusion Criteria:

Healthy participants
Patients in pain: suffering from persistent pain more days than not, 3/10 in intensity on a numerical rating scale, for at least 6 weeks or more.

Exclusion Criteria:

Any DSM diagnosis
diabetes
food allergies
lactose intolerance
participants seeking to quit smoking or to lose weight
participants on any psychotropic medication including opiate based analgesics (e.g. oxycodone, methadone, suboxone)
pregnant or nursing women
pacemaker or other implanted electrical devices
Participants with a past history of head trauma or seizures
Any past history of illegal drug or alcohol misuse
Participants who cannot undergo an MRI scan.
Intervention: Fluvoxamine
Trial phase: Phase 2
ATC code: N06AB08
SMILES: COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.

Fluvoxamine: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
Eligibility criteria:
Inclusion Criteria:

men and woman age 18 and older;
Not hospitalized;
Has recently tested SARS-CoV-2 (COVID-19 virus) positive.
Currently symptomatic with one or more of one or more of the following symptoms: fever, cough, myalgia, mild dyspnea, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat.
Able to provide informed consent.

Exclusion Criteria:

Illness severe enough to require hospitalization or already meeting study's primary endpoint for clinical worsening.
Unstable medical comorbidities including, but not limited to: Severe underlying lung disease (COPD on home oxygen, interstitial lung disease, pulmonary hypertension), decompensated cirrhosis, Congestive heart failure (stage 3 or 4 per patient report and/or medical records).
Immunocompromised (solid organ transplant, BMT, AIDS, on biologics and/or high dose steroids (>20mg prednisone per day)
Unable to provide informed consent (eg moderate-severe dementia diagnosis)
Unable to perform the study procedures
Intervention: Labetalol
Trial phase: Phase 4
ATC code: C07AG01 | C07BG01 | C07CG01
SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 13
Group description: labetalol only

labetalol: 200mg labetalol BID
Eligibility criteria:
Inclusion Criteria:

Postpartum women delivering at Miami Valley Hospital
Diagnosis of gestational hypertension or preeclampsia
Able to provide written informed consent

Exclusion Criteria:

Diagnosis of chronic hypertension
Allergy to study medications
Unable to understand English